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Factors Affecting the Morbidity of Contact Lens–Related
Microbial Keratitis: A Population Study
Lisa Keay,1,2 Katie Edwards,1,2 Thomas Naduvilath,2 Kevin Forde,3 and Fiona Stapleton1,2
PURPOSE. To examine factors influencing the severity of soft
contact lens (SCL)–related microbial keratitis.
METHODS. Cases were detected via surveillance studies in Aus-
tralia and New Zealand. Factors affecting disease severity
(costs, days of symptoms, and 2 or more lines of vision loss)
were examined and included age; gender; delay in SCL re-
moval, seeking consultation, or receiving treatment; overnight
wear; SCL material (hydrogel or silicone hydrogel [SiH]); and
causative organism.
RESULTS. Two hundred ninety-seven cases were identified: 61%
female, age: 35 13 years (mean SD). Treatment costs were
(median [interquartile range]) $760 [1859] and indirect costs
were $468 [1810]. Patients were symptomatic for 7 [11] days,
and vision loss occurred in 14.3% of cases. Cases with patho-
genic causative organisms (66/297, 22%) were 11.4 times (95%
confidence interval [CI], 4.2–30.9) more likely to result in
vision loss, had longer duration of symptoms (21 [40] vs. 6 [8]
days, P  0.001) and incurred higher costs (5,512 [14,733] vs.
1,048[8,325], P 0.001). Delays (12 hours) before treatment
increased the likelihood of vision loss (P  0.048) disease
duration (P  0.004), and associated costs (P  0.009). Re-
moteness increased the risk of vision loss (odds ratio [OR] 
5.1; 95% CI 1.6–16.6), and individuals over 28 years of age had
longer disease duration (P 0.02). In overnight wear and after
adjustment for culture result and treatment delays, SiH wearers
had slightly shorter disease duration (4 [4] vs. 7 [10] days, P 
0.02) but a rate of vision loss and cost similar to those of
hydrogel wearers.
CONCLUSIONS. The causative organism was the major determi-
nant of severity; however, modifiable factors such as delays in
treatment had considerable influence. Duration of symptoms
was shorter in SiH wearers, but other factors dominated dis-
ease outcome in this population study. (Invest Ophthalmol Vis
Sci. 2006;47:4302–4308) DOI:10.1167/iovs.06-0564
Contact lenses are a major cause of microbial keratitis in allcountries where they are widely available, particularly in
young adults.1–3 The condition ranges widely in severity from
a painful episode that resolves quickly with intensive antibiotic
therapy to an infection requiring long periods of hospitaliza-
tion and surgery for restoration of vision. Loss of vision is
infrequent in contact lens–related microbial keratitis, reported
in 11% to 13% of cases.4,5
National surveillance studies of contact lens–related micro-
bial keratitis conducted in Australia (Stapleton et al. IOVS
2005;46:ARVO E-Abstract 5025) and New Zealand in 2003 and
2004 provided a unique opportunity to review the severity of
disease including hospital cases and those managed in the
community. The purpose of this analysis was to document the
morbidity of contact lens–associated microbial keratitis in a
large case series and to determine the factors that increased the
likelihood of a poor outcome.
The morbidity of contact lens–related keratitis is strongly
influenced by the pathogenicity of the causative organisms. For
example, Pseudomonas infections are of larger diameter, re-
quire more outpatient visits, and are more likely to be associ-
ated with vision loss and hospital admission.4 Gram-negative
keratitis is associated with greater treatment costs.3 In addition
to the causative organism, the time taken to receive treatment
can have a major impact on disease outcome. Microbial kera-
titis, which presents 24 hours after the onset of symptoms,
has been shown to incur higher treatment costs.3 Delay in
referral is associated with the eventual need for penetrating
keratoplasty,6 and initial inappropriate therapy is associated
with severe disease7 and treatment failure.8
Silicone hydrogels (SiH) are new soft contact lenses that
allow higher levels of oxygen to the cornea, providing benefits
for corneal health during contact lens wear. Recent research
has shown that the risk of infection in overnight wear is the
same as for hydrogel contact lenses (Stapleton et al. IOVS
2005;46:ARVO E-Abstract 5025; Radford et al. IOVS 2005;46:
ARVO E-Abstract 5026). One study has suggested that events
with SiH contact lenses are less severe.9
Although several studies of contact lens–related microbial
keratitis have documented the rate of vision loss,4,5,10 cost
analysis is a novel approach to measuring the outcome of the
disease. Other studies have quoted rate of hospitalization, hos-
pital bed days, or number of outpatient visits4; however, only
a minority of patients with contact lens–related microbial ker-
atitis are hospitalized for treatment—30% of cases in this study.
Cost analysis offers the possibility of a continuous scale for
resources involved in disease treatment, both hospital based
and in private clinics.
The purpose of this study was to explore different indica-
tors of severity and to examine factors influencing the severity
of contact lens–related microbial keratitis. The effect on dis-
ease severity of causative organism and treatment delay was
examined, in combination with the effect of newly available
SiH materials.
METHODS
Inclusion and Exclusion Criteria
Cases of contact lens–related microbial keratitis in 15- to 64-year-olds,
wearing contact lenses for the correction of simple refractive error
were detected through surveillance of ophthalmic practitioners in
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Australia and New Zealand. As this analysis was not designed to
produce incidence rates, cases were included from a 4-month pilot
study in Australia and New Zealand involving 67 practitioners11 and
12-month national surveillance studies of Australia and New Zealand.
This research was conducted in compliance with the tenets of the
Declaration of Helsinki as revised in 2000. The protocol was approved
by the Human Research Ethics Committee at the University of New
South Wales and at local committees of regional health districts in
Australia and New Zealand.
All the cases reported in these surveillance studies were reviewed
for their eligibility. Aphakes, keratoconics, and wearers using lenses for
medical indications were excluded. Diagnostic criteria were a corneal
infiltrate with overlying epithelial defect, which was either culture
proven or was associated with at least one of the following: lesion
within the central 4 mm, anterior chamber reaction, or significant
progressive pain. Cases were excluded from analysis when it was not
possible to assess eligibility, because of lack of information.
Detailed information was sought on clinical presentation, microbi-
ologic testing, treatment, and disease resolution. Subjects were inter-
viewed by telephone, at least 1 month after the event, regarding
healthcare and symptoms experienced.
Indicators of Disease Severity
Visual Outcome. Any reduction in vision was assessed using
best corrected Snellen letter acuity or pinhole acuity if available. Loss
of vision was gauged in comparison to the unaffected eye. Nearly all
cases were unilateral; however, when both eyes were affected, the
amount of vision loss was calculated using the worse eye and a
standard referent of 6/6 Snellen acuity. Similarly, if there was amblyo-
pia in the unaffected eye, a standard referent of 6/6 was used for
comparison. As cases were reported from many clinics across Australia
and New Zealand, it was not possible to standardize the measurement
of visual acuity including the type of chart used. Visual outcome was
categorized as loss of 2 or more lines, 10 or more lines of letter acuity,
or no loss of vision.
Cost Analysis. Component costs were estimated by reviewing
the cost of treatment of a series of cases of microbial keratitis at an
Australian tertiary referral hospital.3 This analysis yielded values for
components of treatment—namely, hospital bed days, hospital outpa-
tient clinic visits, and emergency department visits. Medications and
pathology testing costs were estimated from commercial sources, as
these are subsidized by the Australian government under the National
Health Insurance Scheme. In cases that were treated in private clinics,
costs of visits to general medical practitioners, optometrists, and pri-
vate ophthalmologists were estimated from scheduled fees.
Indirect costs were calculated for each case and included days off
work for the patient, carers’ days off work, and purchase of spectacles.
Days off work were allocated a value from the Australian average
national wage in 2004 (Australian Bureau of Statistics). New spectacles
when required were allocated a value estimated from retail prices. If
not stated, days off work were estimated from hospital bed days and
number of medical visits. If not stated, carers’ days were estimated by
using 0.1 days per visit (if patient was admitted or had more than five
visits) and full days for administering intensive antibiotic therapy.
All costs were calculated in Australian dollars. New Zealand cases
were costed using the estimates of component costs from Australia.
There would be some differences in component costs between the
two countries; however, better comparability of the cases was antici-
pated by this methodology. There is also considerable similarity be-
tween the level of training and mode of practice between ophthalmol-
ogists and optometrists in the two healthcare systems.
Disease Duration. Disease duration was defined by the number
of days that symptoms including blurred vision, discomfort, photopho-
bia, discharge, and ocular redness and swelling were experienced. If
the patient and the practitioner both supplied data on disease duration,
the maximum value was taken.
Factors Affecting Disease Outcome
Causative Organisms. There were multiple laboratories from
which results for microbial analysis of corneal scrape samples were
supplied so the criteria for a positive culture could not be standardized.
In some cases, the laboratory report was available. In these cases
results were considered culture negative if the report stated that the
organism was grown on one medium only or only after extended
periods of incubation, if the organism was considered a contaminant,
or if there was no growth on any media. Other results were reported
by the treating practitioner and would have been subject to interpre-
tation of the laboratory report.
Treatment. Information from interviews with patients (n  90)
or from case histories (190) was used to determine the delays in
contact lens removal, seeking consultation, and receiving treatment.
Appropriate therapy was defined as intensive antimicrobial therapy
such as fluoroquinolone monotherapy, an aminoglycoside and cepha-
losporin duotherapy for bacterial keratitis, or accepted therapy for
fungal or amoebic keratitis. Presumed microbial keratitis which was
initially treated with chloramphenicol (Chloromycetin; Pfizer Australia
Pty Ltd., West Ryde, NSW, Australia) fucithalmic acid, or over-the-
counter preparations or were self-medicated were classified as initial
inappropriate therapy.
The effect of rural versus metropolitan healthcare was examined using
the Accessibility and Remoteness Index of Australia (ARIA).12 Cases were
grouped into those highly accessible to healthcare versus the remainder
(accessible to very remote) for the Australian cases. The remoteness of the
locations of New Zealand cases could not be analyzed quantitatively, as no
parallel index was available for New Zealand.
The case histories of the patients with treatment delays were
examined individually. Reasons for delays were categorized as time
delays (waiting for appointments, waiting to see a doctor in emergency
departments), travel time, or delays because the initial treatment was
inappropriate. The proportion where the delay was because initial
treatment was inappropriate was determined, and the types of treat-
ments received were documented.
Contact Lens Group. Contact lens wear was grouped into
overnight use or daily wear and further by hydrogel and SiH materials.
Hydrogel lenses were all soft contact lenses excluding SiH lenses.
Statistical Analysis
Univariate analyses were performed using Fisher exact test, 2, t-test,
and one-way ANOVA based on binary or continuous outcome vari-
ables. Log transformation was performed on total costs and duration of
symptoms due to their large variance before analysis. The association
of factors with binary outcomes was summarized using odds ratios
(ORs), their confidence intervals, and population-attributable risk. The
association of factors with continuous outcomes was summarized by
using R2. Multivariate analysis was performed with logistic and linear
regression for binary and continuous outcome variables, respectively.
Standard modeling procedures such as stepwise backward followed by
the forward method were adopted. Confounders and interactions were
explored. Measures of calibration and discrimination were reported.
Analyses were performed with commercial software (SPSS ver. 12 for
Windows; SPSS Inc., Chicago, IL, and STATA ver. 7, Intercooled STATA
for Windows; STATA Corp., College Station, TX).
The effect of contact lens material in overnight wear was examined
further with a paired t-test, matching cases for causative organism and
treatment delays, with the investigator masked to disease outcome.
RESULTS
A total of 388 cases of contact lens–related microbial keratitis
were reported to the study center. There were 38 (9.8%) cases
that did not meet the eligibility criteria and 53 (13.7%) in
which there was insufficient information to grade the severity.
Data were analyzed for 260 cases from Australia and 37 from
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New Zealand. The smaller case series from New Zealand was
because of the smaller population. The mean age of subjects
was 35  13 years, and gender distribution was 61% female
and 39% male (n  297).
Measures of Disease Severity
Visual Outcome. The proportion with known visual out-
come was 269 of 297 subjects. In Figure 1, the data are
restricted to the cases reported nationally in Australia within
the 12-month surveillance study (n 221). The corresponding
rate of vision loss was 14.3%.
Costs. Indirect costs could be calculated for 272 cases.
Direct costs correlated well with indirect costs (R2  0.64;
ANOVA, indirect costs  0.8  direct costs  72; P  0.001),
so indirect costs were estimated from direct costs in an addi-
tional five cases. Direct costs mainly comprised medical visits
and hospital bed days, and medications comprised 15% of total
costs on average. The major component of indirect costs were
days off work for the subject (2 [9]; median[interquartile
range]) and their carer (0.7 [0.5]). Assistance from a carer was
required in 60% of cases.
Direct costs ($760 [1859]) were generally higher than indi-
rect costs ($468 [1810], median [inter-quartile range]), and
both types of costs were widely distributed (Fig. 2).
Disease Duration. Contact lens–related microbial keratitis
had a typical duration of symptoms of 7 [11] days (median
[inter-quartile range]), and 60% resolved in 8 days or fewer
(Fig. 3). There were some cases with long duration of symp-
toms, particularly where visual symptoms of blur or photopho-
bia persisted past the resolution of redness, pain, and irritation.
Of the cases in which symptoms persisted for longer than 1
month, 70% (17/23) had permanent vision loss.
Factors Affecting Disease Outcome
Causative Organisms. A total of 183 (62%) of 297 subjects
had a corneal scrape performed. There were 11 cases in which
the results of the corneal scrape were not available and 4 in
which the sample was insufficient for conclusive analysis.
Of the remaining 168 cases, there were 83 (49.4%) that
were culture proven. There were 53 samples reported as ster-
ile, 29 with growth on one medium only, and a further 3
FIGURE 1. Rate of reduction in vi-
sual acuity, limited to cases detected
during a 12-month surveillance pe-
riod in Australia (n  221).
FIGURE 2. Frequency distribution of
direct and indirect costs in Australian
dollars (n  277).
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samples in which the organism isolated was considered to be
a contaminant rather than a causative organism.
Among the culture-proven cases, amoeba (4/83, 4.8%) and
fungal (3/83, 3.6%) keratitis were rare. The majority of culture-
proven cases were Gram-negative keratitis 48/83 (57.8%). Of
the Gram-negative samples, Pseudomonas spp. were the most
commonly isolated organisms present in 37 (77.1%) of 48
followed by Serratia spp. In 9 or (18.8%) 48. There were no
significant differences in the spectrum of organisms cultured
from corneal infections associated with SiH and hydrogel ma-
terials (2 test, P  0.3).
Culture proven Gram-negative, Nocardia, amoebic, or fun-
gal keratitis cases were grouped together, in the analysis of the
effect of causative organism on severity. This group comprised
66 (22.2%) of 297 cases. The group had particularly severe
disease outcomes in rate of vision loss, costs of disease, and
duration of symptoms (Table 1). A confirmed pathogenic caus-
ative organism accounted for 51% of the risk of loss of vision
(PAR%).
Treatment. A total of 70 (56%) of 125 of persons delayed
4 hours before removing their contact lenses; the median
delay of those who waited before removing contact lenses was
over 18 hours (19 [42]; median [IRQ]). There were 103 (61%)
of 168 persons who delayed 24 or more hours before seeking
consultation (48 [48]). A significant portion, 55 (33%) of 168,
experienced a delay of 12 or more hours before commencing
appropriate therapy (24 [42]).
Although delays in contact lens removal and seeking con-
sultation did not influence disease severity, delays in receiving
appropriate therapy did influence the costs associated with the
disease, duration of disease, and rate of loss of best corrected
visual acuity (Table 1). When all factors were considered in the
mulitvariate models, delays in treatment increased costs asso-
ciated with disease and disease duration, but did not determine
visual outcome. Most cases of infection (85%) occurred in areas
of Australia that were highly accessible to healthcare (ARIA
category HA). Remoteness to healthcare increased the likeli-
hood of loss of 2 or more lines of vision (Table 1) and ac-
counted for 15% of the risk (PAR%). Remoteness did not cor-
relate with delays in receiving treatment (2 P  0.6).
The group who had delays of 12 or more hours before
receiving appropriate therapy predominantly presented to gen-
eral medical practitioners (30/53, 57%), to optometrists (17/
53, 32%), and to hospital accident and emergency departments
(6/53, 11%). The majority of the delays (47/55) were due to not
receiving appropriate treatment at the initial consultation and
included initial treatment with topical chloramphenicol (27/
47), fucithalmic ointment (1/47), or miscellaneous low-dose
antibiotic drops from general practitioners (8/47); receiving no
treatment (1/47); self-medicating (2/47); or using over-the-
counter preparations (5/49). Two patients received a steroid as
the initial treatment, one from a general practitioner and one
from a private ophthalmologist. A case of Acanthamoeba ker-
atitis was initially treated with acyclovir before final successful
treatment with polyhexylmethyl biguanide, chlorhexidine, and
propamidine isethionate (Brolene; Sanofi-Aventis, Ltd., Guild-
ford, UK). Those with delays in treatment were more likely to
be treated initially by a nonophthalmic practitioner (32/55,
62%) than were those who did not experience any delays in
treatment (9/113, 8%; P  0.001). The delay in time to treat-
ment was accounted for by geographic remoteness or waiting
for appointments in a small number (8/55, 15%).
Contact Lens Group. There were a large number of cases
in which the soft lens material and overnight wear status were
not confirmed (n  109) so the total dataset for this analysis
was 178 cases (Fig. 4). Modalities unpopular in Australia and
New Zealand such as hydrogel extended wear were used in
few cases (n  12).
Univariate analysis (Table 1) showed that the class of hy-
drogel material in combination with an overnight wearing
schedule had no effect on disease severity (P  0.1), and
multivariate modeling confirmed that the causative organism
and delays in receiving treatment were more influential. Paired
analysis, controlling for these other factors showed some ben-
eficial effect on disease duration (Table 2). The average age was
not different between the two groups (33  14 vs. 32  12;
P  0.9) and the SiH group comprised slightly fewer males
(8/14 vs. 6/14, P  0.4). There was a shorter disease duration
in those who wore SiH lenses overnight (Table 2), but rate of
vision loss and associated costs were similar.
Multivariate Analysis
The univariate analysis in Table 1 shows that there were several
factors that influenced disease outcome. Delays in receiving
appropriate treatment correlated highly with initial treatment
by a nonophthalmic practitioner, and so both factors were not
used in the multivariate modeling.
Two factors were identified that predicted the likelihood of
loss of 2 or more lines of best corrected visual acuity (goodness
of fit: P  0.690, area under the receiver operating character-
istic [ROC] curve: 0.813  0.045; 95% confidence interval [CI]
FIGURE 3. Frequency distribution of
the duration of symptoms in days.
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0.72–0.90]). Culture-proven cases in which Gram-negative or-
ganisms, Nocardia species, fungi, or Acanthamoeba were
identified were 11.4 times more likely to cause loss of vision
(95% CI, 4.2–30.9). The other factor was remoteness of health-
care which increased the likelihood of loss of vision by 5.1
times (95% CI, 1.6–16.6).
Total costs associated with disease were influenced by
the causative organism once again but also by delays in
treatment (R  0.546; R2  0.298; overall significance F 
33.9, P  0.001). The causative organism was a more potent
factor (partial eta (r) squared  0.24, P  0.001), but delay
in treatment also increased costs (partial eta (r) squared 
0.04, P  0.008).
Similar to costs, disease duration was influenced by the
culture result and delays in treatment, but in addition persons
over the age of 28 years had longer disease duration (R 
0.496; R2  0.246; overall significance, F  15.5, P  0.001).
The causative organism had the strongest effect (partial eta (r)
squared  0.12, P  0.001). Age (partial eta (r) squared 
0.07, P 0.001) and treatment delays (partial eta (r) squared
0.06, P  0.004) had similar influence on disease duration.
FIGURE 4. Categorization of cases of microbial keratitis in soft contact
lens wearers in daily or extended wear (n  251) and hydrogel or SiH
(n  178) lenses.
TABLE 1. Univariate Analysis of Effect of Various Factors on the Indicators of Severity
Indicator of Severity Factor P OR (95% CI) /r2*
Age 28 years 28 years
Vision loss (2 lines)† 12/94 (13%) 35/176 (20%) 0.2 1.7 (0.8–3.4)
Total cost ($AU)‡ 1,298 [14,737] 1,297 [8,325] 0.7 0.001
Duration symptoms (days)‡ 7 [11] 7 [17] 0.02 0.022
Gender Female Male
Vision loss (2 lines)† 29/167 (17%) 18/102 (18%) 1.0 1.0 (0.5–1.9)
Total cost ($AU)‡ 1,336 [14,737] 1,125 [6,627] 0.1 0.009
Duration symptoms (days)‡ 7 [11] 7 [11] 0.3 0.004
Corneal scrape ND/Sterile/Gram positive Gram negative/Other
Vision loss (2 lines)† 18/206 (9%) 29/57 (51%) <0.001 10.8 (5.3–22.0)
Total cost ($AU)‡ 1,048 [8,325] 5,512 [14,733] <0.001 0.163
Duration symptoms (days)‡ 6 [8] 21 [40] <0.001 0.147
CL Removal No delay Delay 4 hours
Vision loss (2 lines)† 7/51 (14%) 9/64 (14%) 1.0 1.0 (0.4–3.0)
Total cost ($AU)‡ 1,795 [14,578] 1,529 [6,931] 0.5 0.004
Duration symptoms (days)‡ 7 [14] 7 [16] 0.6 0.002
Consultation No Delay Consultation Delay 24 hours
Vision loss (2 lines)† 10/59 (17%) 18/97 (19%) 0.8 1.1 (0.5–2.6)
Total cost ($AU)‡ 1,541 [14,578] 1,576 [7,310] 0.2 0.009
Duration symptoms (days)‡ 7 [11] 7 [15] 0.8 0.000
Treatment No delay Delay 12 hours
Vision loss (2 lines)† 14/104 (14%) 14/52 (27%) 0.048 2.4 (1.0–5.4)
Total cost ($AU)‡ 1,336 [8,305] 3,397 [14,706] 0.001 0.070
Duration symptoms (days)‡ 6 [11] 10 [23] 0.001 0.080
Treating Practitioner Ophthalmic Non-ophthalmic
Vision loss (2 lines)† 30/181 (17%) 13/59 (22%) 0.3 1.4 (0.7–3.0)
Total cost ($AU)‡ 1,257 [14,751] 1,842 [8,252] 0.04 0.017
Duration symptoms (days)‡ 7 [9] 14 [20] 0.005 0.037
Remoteness Highly Accessible MA-Very Remote
Vision loss (2 lines)† 21/131 (16%) 8/23 (35%) 0.04 2.8 (1.1–7.4)
Total cost ($AU)‡ 1,488 [14,731] 1,469 [6,792] 0.8 0.000
Duration symptoms (days)‡ 7 [14] 10 [24] 0.2 0.012
CL Type and Overnight Wear SiH EW H EW SiH DW H DW
Vision loss (2 lines)† 7/70 (10%) 3/11 (27%) 3/15 (20%) 13/76 (17%) 0.4 §
Total cost ($AU)‡ 1,162 [5,897] 1,301 [6,592] 1,361 [5,727] 1,561 [14,744] 0.2 0.026
Duration symptoms (days)‡ 5 [9] 7 [8] 7 [10] 7 [15] 0.6 0.011
Bold P indicates a significant effect. $AU, Australian dollars; MA, moderately accessible; CL, contact lens; ND, not done; DW, daily wear; EW,
extended wear.
* Summary of associations expressed as OR (95% CI) for vision loss, r square for total cost and symptom duration.
† % of cases with loss of 2 or more lines best corrected visual acuity.
‡ Median [IQR].
§ SiH EW 0.5 (0.2–1.4), H EW 1.8 (0.4–7.8), SiH DW 1.2 (0.3–4.9), H DW 1 (referent).
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DISCUSSION
A pathogenic causative organism is the primary determinant of
disease outcome in contact lens–related microbial keratitis.
However, modifiable factors such as delays in treatment appear
to have considerable influence on outcome. Cost analysis and
symptom duration are useful measures of morbidity for a con-
dition that ranges widely in severity, but is rarely associated
with vision loss.
In this analysis, multivariate modeling was limited by the
sample size, comparing within a group of cases of contact
lens–related microbial keratitis in which a severe outcome
occurs in a small subgroup. The models were poorly predictive
for cost and disease duration (R2  0.3) but predicted the
likelihood of loss of vision from the culture result and remote-
ness of healthcare with a high level of confidence (area under
ROC curve, 81.3%). One of the advantages of this study was the
large series of close to 300 cases and the depth of information
on both hospital and private clinic cases.
The major determinant of disease outcome in contact lens–
related microbial keratitis is the causative organism, which
affects rate of vision loss, associated costs, and duration of
symptoms. Similar to previous studies,3,4,9,13–16 we found that
Pseudomonas species were the most common causative or-
ganism in contact lens–related microbial keratitis, accounting
for approximately half of the culture-proven infections. Other
rare but highly pathogenic organisms implicated in contact
lens–related infections were Nocardia species, Acan-
thamoeba, and fungi.
Treatment delays after presentation to a healthcare provider
affected visual outcome, associated costs, and duration of dis-
ease. As delay in treatment is a modifiable factor, better edu-
cation of primary healthcare providers about timely diagnosis,
treatment, and appropriate referral of contact lens–related mi-
crobial keratitis is indicated.17 Remoteness of healthcare also
affected the likelihood of loss of vision. The fact that remote-
ness did not correlate with treatment delays suggests that other
factors may be at play in remote Australia, which differs in
climate and other environmental factors such as water supply.
This finding has implications for advice to contact lens wearers
in rural communities and for those traveling to remote loca-
tions.
The length of time from onset of symptoms to contact lens
removal or presentation to a healthcare provider did not cor-
relate with outcome. Both of these actions are taken by the
individual and would be in response to the symptoms experi-
enced. In effect, people would seek advice sooner in severe
disease, which is typically associated with higher levels of pain
and distress. In milder, less-progressive disease, they may delay
longer before seeking treatment or removing their contact
lenses, with limited effect on disease outcome. A study of
corneal infiltrative events associated with contact lens wear
also found that long delays in presentation were associated
with milder disease.18
In this study, we found that cases in those aged 28 years and
older had longer disease duration than did those in younger
persons. More severe outcome has been shown in patients
older than 60 years6,19; however, we found an age effect, even
within a younger age range.
Although the cases in the population study showed some
trends toward less-severe outcome with SiH materials, the
relatively low number of cases in hydrogel extended wear (11
cases) in this population study limited the full exploration of
these differences. In Australia and New Zealand, extended
wear of hydrogel materials is not recommended by contact
lens practitioners and consequently comprises as little as 2% of
the lens-wearing population.20 Population studies therefore
yield fewer cases of infections in hydrogel extended wear.
In the paired analysis, when the effect of high oxygen
permeability in SiH lenses was isolated, there was a small but
statistically significant reduction in disease duration compared
with hydrogel lenses in overnight wear. Although this is en-
couraging, it remains that very serious infections can still occur
with SiH contact lenses, especially with highly pathogenic
organisms and delays in receiving treatment.
Our rate of reduction in best corrected visual acuity of 2 or
more lines (14%) is similar to that found in other population-
based studies not restricted by age (12%–13%).4,5 Cost analysis
was used to measure severity and the purpose was not to
estimate definitively the cost of treating contact lens–related
keratitis, but rather to investigate relative costs and identify
factors that increase costs. Both cost analysis and disease du-
ration identified delays in treatment as a factor contributing to
poor outcome, whereas vision loss was only predicted by the
pathogenicity of the causative organism and remoteness.
There are always limitations to the accuracy of cost analysis
in healthcare, particularly when multiple centers are involved
that may have different protocols for treatment. However, both
Australia and New Zealand have nationalized health services,
and there is some uniformity to the charges associated with
medical treatment. A nationalized health service means that
there is often a distinction between what a patient is charged
for a service and the actual cost of providing that service. In
this analysis for in-hospital treatment we used the average cost
of a hospital stay, whereas costs of out-of-hospital treatment
were estimated using out-of-pocket expenses by patients. De-
spite limitations, cost analysis offers further perspective on the
burden of disease.
Societal costs of days missed at work have been analyzed in
other acute diseases,21 and we chose to include indirect costs
in our analysis of the costs of contact lens–related microbial
keratitis. The population affected by contact lens–related mi-
crobial keratitis is of working age. Indirect costs due to time off
work are therefore relevant and were a major component in
the financial burden of disease, comprising 44% of total costs.
In this study, we investigated new means of quantifying the
severity of contact lens–related microbial keratitis, including
cost analysis and duration of symptoms. Successful medical
treatment of disease is achieved in a large proportion of cases,
with very few progressing to permanent loss of vision, and so
supplementary measures of severity have descriptive merit in
quantifying disease outcome. The causative organism is the
TABLE 2: Comparison of Outcome Measures for Matched Pairs of Silicone Hydrogel and Hydrogel Cases
in Overnight Wear
Silicone Hydrogel Hydrogel P
Rate of vision loss (%) 2/13(15.4%) 3/14 (21.4%) 1.0*
Total costs 1,409 [4,688] 1,288 [1,183] 0.5
Symptom duration 4 [4] 7 [10] 0.02
n  28.
* Fisher’s exact test.
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dominant factor in determining disease severity, but modifiable
factors such as delays in receiving appropriate therapy have
considerable influence. These findings highlight the impor-
tance of availability of high-quality ophthalmic healthcare and
specific advice for contact lens wearers to optimize disease
outcome in the rare event of a corneal infection associated
with contact lens use.
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